News
Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...
StockStory.org on MSN11h
Biogen Earnings: What To Look For From BIIBBiotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen ...
Biogen Inc. (NASDAQ:BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc. (NASDAQ:BIIB) declared that it would invest $2 billion to its existing North Carolina ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...
StockStory.org on MSN8d
Biogen (BIIB) Stock Trades Down, Here Is WhyWhat Happened? Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist ...
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some ...
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most undervalued stocks. Biogen Inc. (NASDAQ:BIIB) is a global biotechnology leader ...
In a report released yesterday, Geoff Meacham from Citi maintained a Hold rating on Biogen, with a price target of $125.00. The company’s shares closed yesterday at $122.68. Take advantage of TipRanks ...
Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their products. The EMA's Committee for Medicinal ...
Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc.
StockStory.org on MSN15d
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics StocksAs the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. Over the next few ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results